Research progress of driving gene and molecular targeting therapy for non-small cell lung cancer / 中国基层医药

The morbidity and mortality of lung cancer are the highest in China, and the non-small cell lung cancer(NSCLC) is the first one, accounting for about 80% of lung cancer.NSCLC includes squamous cell carcinoma, adenocarcinoma, etc.Because of the slow growth of lung cancer cells and the late diffusion and metastasis, most of the patients were in late stage and lost the best period of surgical treatment.In recent years, molecular targeted therapy for specific genes has become an important strategy for the treatment of NSCLC.Multiple target genes, such as EGFR, KRAS, BRAF and EML4-ALK have been identified.This article reviews the related driving genes and molecular targeted therapy of NSCLC, expecting to be helpful to the individualized treatment of advanced NSCLC patients.

The relationship between hereditaryspherocytosis and protein 4.2 / 医学研究生学报

Hereditary spherocytosis (HS) is a common hereditary hemolytic disease. The molecular pathogenesis of HS involves gene mutations, which lead to deficiency or absence of erythrocyte membrane proteins. Five major pathogenic genes of SPTA1, SPTB, ANK1, SLC4A1 and EPB42 had been found, and they encode α-spectrin, β-spectrin, ankyrin, band 3 and protein 4.2 respectively. There are many reports about gene mutations of EPB42, which cause deficiency or absence of protein 4.2 abroad. However, few scholars study the correlation between HS and protein 4.2 in China. This review describe the advances of the relationship between HS and protein 4.2 in detail.